UNIVERSE PHARMACEUTICAL-CL A (UPC) Fundamental Analysis & Valuation

NASDAQ:UPC • KYG9442G1385

Current stock price

3.13 USD
+0.07 (+2.29%)
At close:
3.15 USD
+0.02 (+0.64%)
After Hours:

This UPC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. UPC Profitability Analysis

1.1 Basic Checks

  • In the past year UPC has reported negative net income.
  • In the past year UPC has reported a negative cash flow from operations.
  • In the past 5 years UPC reported 4 times negative net income.
  • In the past 5 years UPC reported 4 times negative operating cash flow.
UPC Yearly Net Income VS EBIT VS OCF VS FCFUPC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M 10M

1.2 Ratios

  • UPC's Return On Assets of -5.30% is fine compared to the rest of the industry. UPC outperforms 72.25% of its industry peers.
  • UPC has a Return On Equity of -6.54%. This is in the better half of the industry: UPC outperforms 77.49% of its industry peers.
Industry RankSector Rank
ROA -5.3%
ROE -6.54%
ROIC N/A
ROA(3y)-11.3%
ROA(5y)-6.49%
ROE(3y)-16.42%
ROE(5y)-9.77%
ROIC(3y)N/A
ROIC(5y)N/A
UPC Yearly ROA, ROE, ROICUPC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60

1.3 Margins

  • UPC has a Gross Margin (35.28%) which is in line with its industry peers.
  • In the last couple of years the Gross Margin of UPC has declined.
  • UPC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 35.28%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.51%
GM growth 5Y-5.12%
UPC Yearly Profit, Operating, Gross MarginsUPC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. UPC Health Analysis

2.1 Basic Checks

  • UPC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for UPC has been increased compared to 1 year ago.
  • The number of shares outstanding for UPC has been increased compared to 5 years ago.
  • The debt/assets ratio for UPC is higher compared to a year ago.
UPC Yearly Shares OutstandingUPC Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 100K 200K 300K 400K 500K
UPC Yearly Total Debt VS Total AssetsUPC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

2.2 Solvency

  • UPC has an Altman-Z score of 0.67. This is a bad value and indicates that UPC is not financially healthy and even has some risk of bankruptcy.
  • UPC has a Altman-Z score of 0.67. This is comparable to the rest of the industry: UPC outperforms 49.74% of its industry peers.
  • UPC has a Debt/Equity ratio of 0.13. This is a healthy value indicating a solid balance between debt and equity.
  • UPC has a Debt to Equity ratio (0.13) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Altman-Z 0.67
ROIC/WACCN/A
WACC4.66%
UPC Yearly LT Debt VS Equity VS FCFUPC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M

2.3 Liquidity

  • A Current Ratio of 4.07 indicates that UPC has no problem at all paying its short term obligations.
  • UPC's Current ratio of 4.07 is in line compared to the rest of the industry. UPC outperforms 58.12% of its industry peers.
  • A Quick Ratio of 3.90 indicates that UPC has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 3.90, UPC is in line with its industry, outperforming 59.69% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.07
Quick Ratio 3.9
UPC Yearly Current Assets VS Current LiabilitesUPC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. UPC Growth Analysis

3.1 Past

  • UPC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 99.48%, which is quite impressive.
  • The Revenue for UPC has decreased by -22.44% in the past year. This is quite bad
  • Measured over the past years, UPC shows a very negative growth in Revenue. The Revenue has been decreasing by -10.27% on average per year.
EPS 1Y (TTM)99.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100.34%
Revenue 1Y (TTM)-22.44%
Revenue growth 3Y-23.66%
Revenue growth 5Y-10.27%
Sales Q2Q%-14.14%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
UPC Yearly Revenue VS EstimatesUPC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

More info and screens

Find the best growth stocksShow best growing peers

0

4. UPC Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for UPC. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
UPC Price Earnings VS Forward Price EarningsUPC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
UPC Per share dataUPC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80 100

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. UPC Dividend Analysis

5.1 Amount

  • No dividends for UPC!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

UPC Fundamentals: All Metrics, Ratios and Statistics

UNIVERSE PHARMACEUTICAL-CL A

NASDAQ:UPC (4/13/2026, 8:00:02 PM)

After market: 3.15 +0.02 (+0.64%)

3.13

+0.07 (+2.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-29
Earnings (Next)07-20
Inst Owners5.19%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.75M
Revenue(TTM)17.86M
Net Income(TTM)-3.67M
Analysts0
Price TargetN/A
Short Float %0.85%
Short Ratio0.46
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.1
P/FCF N/A
P/OCF N/A
P/B 0.03
P/tB 0.03
EV/EBITDA N/A
EPS(TTM)-10.13
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-9.64
FCFYN/A
OCF(TTM)-9.02
OCFYN/A
SpS31.89
BVpS100.23
TBVpS99.7
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -5.3%
ROE -6.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 35.28%
FCFM N/A
ROA(3y)-11.3%
ROA(5y)-6.49%
ROE(3y)-16.42%
ROE(5y)-9.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.51%
GM growth 5Y-5.12%
F-Score4
Asset Turnover0.26
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 67.1%
Cap/Sales 1.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.07
Quick Ratio 3.9
Altman-Z 0.67
F-Score4
WACC4.66%
ROIC/WACCN/A
Cap/Depr(3y)47.61%
Cap/Depr(5y)51.52%
Cap/Sales(3y)1.17%
Cap/Sales(5y)0.93%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100.34%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-22.44%
Revenue growth 3Y-23.66%
Revenue growth 5Y-10.27%
Sales Q2Q%-14.14%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y63.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y45.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.86%
OCF growth 3YN/A
OCF growth 5YN/A

UNIVERSE PHARMACEUTICAL-CL A / UPC Fundamental Analysis FAQ

What is the ChartMill fundamental rating of UNIVERSE PHARMACEUTICAL-CL A (UPC) stock?

ChartMill assigns a fundamental rating of 1 / 10 to UPC.


Can you provide the valuation status for UNIVERSE PHARMACEUTICAL-CL A?

ChartMill assigns a valuation rating of 0 / 10 to UNIVERSE PHARMACEUTICAL-CL A (UPC). This can be considered as Overvalued.


Can you provide the profitability details for UNIVERSE PHARMACEUTICAL-CL A?

UNIVERSE PHARMACEUTICAL-CL A (UPC) has a profitability rating of 1 / 10.